clinical trial · NCT05463744
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Eli Lilly and Company·phase3·completed·n = 692
Type 1 DiabetesDiabetesInsulin Efsitora AlfaInsulin Degludec
brief summary
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
started
Aug 12, 2022
primary completion
May 7, 2024
completion
May 7, 2024
last updated
Jun 24, 2025
official title
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol